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Background
The prevalence of and risk factors for central nervous system recurrence in patients with
acute promyelocytic leukemia are not well established and remain a controversial matter. 
Design and Methods
Between 1996 and 2005, 739 patients with newly diagnosed acute promyelocytic
leukemia enrolled in two consecutive trials (PETHEMA LPA96 and LPA99) received induc-
tion therapy with all-trans retinoic acid and idarubicin. Consolidation therapy comprised
three courses of anthracycline monochemotherapy (LPA96), with all-trans retinoic acid and
reinforced doses of idarubicin in patients with an intermediate or high risk of relapse
(LPA99). Central nervous system prophylaxis was not given. 
Results
Central nervous system relapse was documented in 11 patients. The 5-year cumulative
incidence of central nervous system relapse was 1.7% (LPA96 3.2% and LPA99 1.2%;
p=0.09). The cumulative incidence was 0%, 0.8%, and 5.5% in low-, intermediate-, and
high-risk patients, respectively. Relapse risk score (p=0.0001) and the occurrence of central
nervous system hemorrhage during induction (5-year cumulative incidence 18.7%,
p=0.006) were independent risk factors for central nervous system relapse. 
Conclusions
This study shows a low incidence of central nervous system relapse in patients with acute
promyelocytic leukemia following therapy with all-trans retinoic acid and anthracycline
without specific central nervous system prophylaxis. Central nervous system relapse was
significantly associated with high white blood cell counts and prior central nervous sys-
tem hemorrhage, which emerged as independent prognostic factors.
Key words: acute promyelocytic leukemia, central nervous system relapse, all-trans
retinoic acid, idarubicin, prognostic factors. 
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Introduction
The central nervous system (CNS) is the most common
site of extramedullary relapse in acute promyelocytic
leukemia (APL), and at least 10% of relapses involve the
CNS.1 However, there is an apparent lack of documented
knowledge about many aspects of this challenging clinical
complication in the context of state-of-the-art treatments
with all-trans retinoic acid (ATRA) and chemotherapy. The
reported incidence of CNS relapses in APL ranges from
0.6% to 2%.2,3 Although CNS involvement is associated
with age3 and BCR3 isoform,3,4 and possibly with the use of
ATRA and the development of differentiation syndrome,5
high white blood cell (WBC) count at presentation appears
to be the most consistent predictive factor.3,6 For patients
without leukocytosis, who have an extremely low risk of
CNS relapse, there is a general consensus that CNS pro-
phylaxis is not indicated.7 In contrast, in patients with APL
and high-risk features presenting with a high WBC count,
some have argued in favor of CNS prophylaxis with
intrathecal chemotherapy.6,8 Available data about disease
outcome after CNS relapse are limited. The GIMEMA
group reported that the survival rates of patients after CNS
relapse and after isolated bone marrow relapse were simi-
lar.2 However, in a joint study by the European APL and
PETHEMA groups, survival rates after CNS relapse were
significantly lower than after bone marrow relapse.3 The
optimal management of APL patients with CNS involve-
ment at first relapse, whether isolated or associated with
bone marrow involvement, has not been assessed critical-
ly.
We analyzed the incidence of and prognostic risk factors
for CNS involvement at first relapse in a large series of
newly diagnosed patients with APL who were enrolled in
two consecutive Programa Español de Tratamiento en
Hematología (PETHEMA) trials (LPA96 and LPA99) and
treated with ATRA and anthracycline monochemotherapy
without CNS prophylaxis. We also evaluated the outcome
of these patients.
Design and Methods
Eligibility for inclusion in the study
The eligibility criteria for enrollment of patients with
genetically diagnosed APL have been described else-
where.9 The study protocol was approved by the Research
Ethics Board of each participating hospital according to the
Declaration of Helsinki.
Therapy of acute promyelocytic leukemia
Patients were included in two successive protocols
(LPA96 and LPA99) that have been previously described.9
Briefly, treatment consisted of induction therapy with
ATRA and idarubicin (AIDA regimen), three consolidation
courses with idarubicin (two courses) and mitoxantrone
(one course) with or without ATRA according to a risk-
adapted strategy,9 followed by maintenance therapy with
ATRA and low-dose chemotherapy with methotrexate
and 6-mercaptopurine.
Prophylaxis and treatment of central nervous system
relapse
Patients did not receive CNS prophylaxis. When CNS
relapse occurred, treatment comprised weekly intrathecal
triple therapy (ITT) with methotrexate, hydrocortisone,
and cytarabine until complete clearance of blasts in the
cerebrospinal fluid, followed by less frequent ITT treat-
ments as consolidation. Some patients received further
craniospinal irradiation at the physician’s discretion.
Systemic treatment with ATRA plus chemotherapy or
arsenic trioxide was also given as induction or consolida-
tion or both, even for patients with isolated CNS involve-
ment. Autologous or allogeneic stem cell transplant was
given, in some cases, as intensification therapy.
Study definitions and end-points
The remission-induction response was assessed accord-
ing to the criteria revised recently by Cheson et al.10
Molecular remission was defined as the disappearance on
an ethidium bromide gel of the PML–RARA-specific band
visualized at diagnosis, using a previously described nest-
ed reverse-transcriptase polymerase chain reaction (RT-
PCR) assay for PML–RARA amplification11 with a sensitiv-
ity level of 10–4. Persistent molecular disease and molecular
relapse were defined as PCR positivity in two consecutive
bone marrow samples collected at the end of consolidation
therapy and at any time after consolidation therapy,
respectively. CNS relapse was confirmed by lumbar punc-
ture and cytological examination of cerebrospinal fluid,
which was performed only in patients with clinically sus-
pected CNS relapse. Morphological and molecular status
was assessed by examining bone marrow aspirates from
all patients at the time of CNS relapse.
Prognostic factors
Twenty-seven characteristics of the patients and disease
were analyzed to establish their relationship to CNS
relapse. In addition to the characteristics listed in Table 1,
the following variables were also considered: serum lactate
dehydrogenase (LDH), peripheral blast count, fibrinogen
level, relapse-risk score, cytogenetics, FLT3-internal tan-
dem duplication (FLT3-ITD) mutation, and a number of
surface antigen markers (CD2, CD7, CD11b, CD34,
CD13, HLA-DR, and CD56). Occurrence of clinically and
radiologically evident CNS hemorrhage at diagnosis or
during induction, and development of differentiation syn-
drome were also included. Differentiation syndrome was
diagnosed according to the presence of two or more of the
symptoms and signs described by Frankel et al.12
Statistical methods
The χ2 test, with Yates’ correction if necessary, was used
to analyze differences in the distribution of variables
between subsets of patients. The probability of CNS
involvement at first relapse was estimated by the cumula-
tive incidence method, and univariate comparison
between the cumulative incidence curves was performed
using the Gray test.14 Isolated bone marrow relapse (molec-
ular or morphological), death in complete remission, and
development of secondary acute leukemia or myelodys-
plastic syndrome was each considered as a competing risk
event. Multivariate analysis was performed using a logistic
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regression model.14 Overall survival after relapse was esti-
mated by the Kaplan–Meier method, and comparisons
were made by the log-rank test.15 The patients’ follow-up
was updated in June 2008, and the median follow-up was
83 months (range, 32-136 months). 
Results
Accrual and patients’ characteristics
Between November 1996 and June 2005, 793 consecutive
patients with a genetic diagnosis of APL were registered
from 82 institutions in Spain, The Netherlands, Belgium,
Argentina, Uruguay, and the Czech Republic (see Appendix).
Details about the non-eligible, non-evaluable, and evalu-
able patients have been reported elsewhere.16,17
The main demographic and baseline characteristics of
the 667 patients who achieved complete remission are
shown in Table 1. Patients enrolled in the LPA96 and LPA99
trials were similar for all baseline characteristics except for
sex (more females were included in the LPA99 trial,
p=0.02).
Incidence and characteristics of central nervous 
system relapse
CNS involvement at first relapse was documented in 11
patients: in eight of these it was isolated (although three
had positive PML–RARA in the bone marrow by RT-PCR)
Table 1. Main demographic and baseline characteristics of 667 acute promyelocytic leukemia patients who achieved complete remission
with the AIDA regimen (study population).
LPA96 LPA99 Total
Characteristic Median (range) n (%) Median (range) n (%) p value Median (range) n (%)
Overall 156 (100) 511 (100) 667 (100)
Age, years 40 (2-73) 39 (2-83) 40 (2-83)
<18 16 (10) 62 (12) 0.65 78 (12)
18-50 92 (59) 308 (60) 400 (60)
51-60 25 (16) 61 (12) 86 (13)
61-70 17 (11) 53 (10) 70 (10)
>70 6 (4) 27 (5) 33 (5)
Sex
Male 89 (57) 238 (47) 0.02 327 (49)
Female 67 (43) 273 (53) 340 (51)
ECOG score 1 (0-3) 1 (0-3) 1 (0-3)
0-1 117 (81) 353 (75) 0.28 470 (77)
2 19 (13) 88 (19) 107 (17)
3 8 (6) 29 (6) 37 (6)
Fever
No 101 (65) 310 (61) 0.45 411 (62)
Yes 55 (35) 195 (39) 250 (38)
WBC count, ×109/L 1.9 (0.3-162) 2.1 (0.2-460) 2.1 (0.2-460)
<3.5 100 (64) 321 (63) 0.51 421 (63)
3.5-10 19 (12) 76 (15) 95 (14)
10-50 30 (19) 80 (16) 110 (17)
>50 7 (4) 33 (6) 40 (6)
Platelet count, ×109/L 21 (1-161) 22 (1-207) 22 (1-207)
<10 31 (20) 90 (18) 0.74 121 (18)
10-40 87 (56) 301 (59) 388 (58)
> 40 38 (24) 119 (23) 157 (24)
Hemoglobin, g/dL 9.6 (4.3-15.2) 9.1 (3-16.9) 9.2 (3-16.9)
≤10 93 (60) 329 (64) 0.27 422 (63)
> 10 63 (40) 181 (36) 244 (37)
Creatinine, mg/dL 0.9 (0.2-1.4) 0.9 (0.2-2.4) 0.9 (0.2-2.4)
≤1.4 156 (100) 489 (99) 0.58 645 (99)
> 1.4 0 (0) 4 (1) 4 (1)
Albumin, mg/dL 4.2 (2.2-6.2) 4 (1.7-6.7) 4 (1.7-6.7)
≤3.5 21 (15) 89 (22) 0.07 110 (20)
>3.5 120 (85) 313 (78) 433 (80)
Coagulopathy
No 34 (22) 127 (25) 0.82 161 (24)
Yes 122 (78) 369 (75) 501 (76)
FAB subtype
Hypergranular 133 (85) 416 (83) 0.74 549 (84)
Microgranular 23 (15) 85 (17) 108 (16)
PML/RARα isoform
BCR1/BCR2 82 (55) 268 (60) 0.30 350 (59)
BCR3 66 (45) 177 (40) 253 (41)
WBC: white blood cell count; FAB: French-American-British.
whereas in three it was simultaneous with overt involve-
ment of the bone marrow. The median time to CNS
relapse was 16 months (range, 6-49 months) compared
with 16 months (range, 5-74 months) for isolated bone
marrow relapse. The characteristics of the patients who
experienced CNS relapse are summarized in Table 2. Seven
patients were female, and four were male. At the time of
the primary APL diagnosis, the median age was 33 years
(range, 6-70 years) and WBC count was 34.5×109/L (range,
1.9–162×109/L). Eight of the 11 CNS relapses occurred in
the 149 patients classified at diagnosis as being at high-risk
(cumulative incidence at 5 years, 5.45%), and the other
three were in the 381 patients classified as being at inter-
mediate-risk (cumulative incidence at 5 years, 0.8%). No
CNS relapses were observed in low-risk patients. Three
patients experienced clinical CNS hemorrhage during
induction therapy. One additional patient (9%) had differ-
entiation syndrome compared with 22 of 73 relapsed
patients (30%) without CNS involvement. The overall 5-
year cumulative incidence of CNS relapse was 1.7%, with
a trend toward a higher incidence in the LPA96 trial (3.2%)
than in the LPA99 trial (1.2%) (p=0.09). The cumulative
incidence of isolated bone marrow relapse was 14.7% in
the LPA96 trial and 10.6% in the LPA99 trial (p=0.08). The
relative frequency of CNS involvement among relapsed
patients overall was 13%: five of 28 relapses (18%) in the
LPA96 trial and six of 56 relapses (11%) in the LPA99 trial.
No extramedullary sites of relapse other than CNS were
observed in either PETHEMA trial.
Treatment of central nervous system relapse
Treatment of CNS relapse included ITT for all patients
except one, who was treated with intrathecal liposomal
cytarabine. Six patients received further CNS irradiation (4
holocranial and 2 craniospinal). Except for two patients,
both with CNS relapse without morphological bone mar-
row involvement, all remaining patients received systemic
treatment (Table 2).
Outcome of patients with central nervous 
system relapse
Of the eight patients with CNS involvement without
morphological relapse in the bone marrow (3 PCR posi-
tive) one died during CNS treatment. The remaining seven
patients achieved a complete clearance of blasts from the
cerebrospinal fluid and relief of symptoms. The subse-
quent outcome of these patients was as follows: (i) two
patients experienced a second relapse and died despite
receiving consolidation therapy with liposomal ATRA or
intensive chemotherapy; (ii) three patients are alive in
complete remission after salvage therapy for a second CNS
or bone marrow relapse; and (iii) two patients did not
relapse after receiving ATRA plus intensive chemotherapy
or arsenic trioxide followed by autologous stem cell trans-
plantation.
The three patients with simultaneous CNS and bone
marrow involvement died during systemic therapy with
ATRA plus intensive chemotherapy (2 patients) or during
aplasia following autologous stem cell transplantation.
Central nervous system relapse in APL
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Table 2. Pretreatment characteristics of patients who had a central nervous system relapse and time of occurrence, treatment, and outcome the relapse.
Sex/age LPA WBC Risk BCR DS CNS Time to BM CNS Systemic Outcome Survival from
(years) trial (x109/L) score bleeding CNS relapse  relapse therapy therapy CNS relapse
(months) (months)
F/6 96 13.6 High 3 No Yes 49 No ITT (x8)+ LPA99 Alive 59
RTh (18 Gy) protocol in CR2
M/32 99 6.2 Interm. 3 No No 10 No ITT (x12) No Alive in CR3 52
F/22 99 66.5 High 3 No No 29 PCR+ ITT (x9) MTZ+AraC Alive 50
(x2)+AutoSCT in CR3
M/29 99 34.5 High 3 No No 13 PCR+ ITT (x6) MTZ+AraC Alive 47
(x1)+AlloSCT in CR3
F/49 99 41 High 1/2 Yes No 27 PCR+ IT L-AraC (x5)+ ATO (x2) + Alive 8
RTc (16 Gy) AutoSCT in CR2
M/33 96 67.9 High 1 No No 16 No ITT (x15) + L-ATRA (x28) Death in 14
RTc (16 Gy) + AutoSCT 2nd relapse
F/50 99 1.9 Interm 3 No No 41 No ITT (x6) + AIDA + Death in 13
RTh (18 Gy) HIDAC 2nd relapse
F/43 96 162 High 3 No No 7 Yes ITT (x3) + MTZ+AraC Death in 5
RTh (20 Gy) (x1)+AutoSCT CR2
F/70 99 68.8 High 1 No Yes 14 No ITT (x6) + No Death in 3
RTh (36 Gy) 1st relapse
F/57 96 7.7 Interm. 1 No No 32 Yes ITT (x4) MTZ + AraC Death in 2
1st relapse
M/16 96 26.7 High 3 No Yes 6 Yes ITT (x1) AIDA + HIDAC Death in 0.5
1st relapse
M: male; F: female;WBC: white blood cell count; CNS: central nervous system; APL: acute promyelocytic leukemia; DS: differentiation syndrome; IT: intrathecal; ITT: intrathecal triple
chemotherapy; RTc: craniospinal radiotherapy; RTh: holocranial radiotherapy; BM: bone marrow; CR: complete remission; ATO: arsenic trioxide; ATRA: all-trans retinoic acid; SCT: stem
cell transplant; MTZ: mitoxantrone; AIDA: ATRA + idarubicin; AraC: cytarabine; HIDAC: high-dose cytarabine; L-AraC: liposomal cytarabine; L-ATRA: liposomal ATRA.
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The median survival was 13 months in patients who had
a CNS relapse and 20 months in those who had isolated
bone marrow relapse (p=0.61).
Prognostic factors for central nervous system relapse
The univariate analysis identified the following charac-
teristics as being associated with CNS relapse: high WBC
count in the peripheral blood at presentation (p<0.0001),
high blast count in the peripheral blood (p=0.0009), both
with a count of 10×109/L as the most significant cut-off;
relapse-risk score (p=0.001); clinical CNS hemorrhage dur-
ing induction chemotherapy (p<0.0001); elevated serum
LDH concentration (p=0.005); FLT3-ITD mutations
(p=0.015); and CD56 positivity (p=0.047) (Table 3).
Multivariate analysis was also carried out: insufficient
data were available for FLT3-ITD mutation status and
CD56 expression. Multivariate analysis identified the fol-
lowing independent prognostic factors for CNS relapse:
relapse-risk score (p=0.0001) (Figure 1A) and clinical CNS
hemorrhage during induction chemotherapy (p=0.006)
(Figure 1B). Because univariate analysis showed a trend for
a lower cumulative incidence of CNS relapse among
patients treated in the LPA99 trial (p=0.09), the LPA96 and
LPA99 trials were compared according to the relapse-risk
group. For high-risk patients, the 5-year cumulative inci-
dences of CNS relapse were 10.8% in the LPA96 trial and
Table 3. Main comparisons of cumulative incidence of central nervous system relapse according to the characteristics of the patients and
disease.
Characteristic Total number CNS 5-year CI p value Multivariate p value
of patients relapse of CNS univariate analysis multivariate
relapse analyses Hazard ratio analysis
n n % (95% confidence interval)
Overall 667 11 1.68
LPA trial
LPA 96 156 5 3.21 0.09 0.08
LPA 99 511 6 1.19
Age, years
≤45 406 7 1.76 0.79 NI
>45 261 4 1.55
Sex
Male 327 4 1.22 0.48 NI
Female 340 7 2.12
WBC count, ×109/L
≤ 10 517 3 0.59 < 0.0001 0.19
>10 149 8 5.45
Platelet count, ×109/L
≤40 497 9 1.85 0.59 NI
>40 169 2 1.18
Blasts in PB, ×109/L
≤10 495 4 0.85 0.0009 0.83
>10 119 6 5.08
Relapse-risk score
Low 136 0 0.00 0.001a 7.0 (1.42–20.70) 0.0001
Intermediate 381 3 0.80
High 149 8 5.45
CNS hemorrhage
No 649 8 1.24 < 0.0001 9.9 (3.22–57.40) 0.006
Yes 18 3 18.75
Coagulopathy
No 161 0 0.00 0.07 0.81
Yes 501 11 2.22
LDH, xULN
≤1 331 1 0.32 0.005 0.06
>1 302 10 3.35
FAB subtype
Hypergranular 549 8 1.49 0.32 NI
Microgranular 108 3 2.78
PML/RARα isoform
BCR1 300 4 1.33 0.37b NI
BCR2 17 0 0.00
BCR3 244 6 2.54
FLT3-ITD
Negative 206 1 0.49 0.015 NIc
Positive 57 3 5.39
CD56
Negative 374 4 1.13 0.047 NIc
Positive 41 2 4.88
aLow risk vs. intermediate risk (p=0.31); low risk vs high risk (p=0.008), intermediate risk vs high risk (p=0.001); bBCR1 vs.BCR3 (p=0.37); cNot included in multivariate
analysis because of missing data in a significant number of patients.CNS: central nervous system; ULN: upper limit of normal value; PB: peripheral blood;WBC: white blood
cell; FAB: French-American-British; CI: cumulative incidence; NI: not included in multivariate analysis.
3.6% in the LPA99 trial (p=0.02; Figure 1C). For interme-
diate-risk patients, the 5-year cumulative incidences were
1.2% and 0.7% in the LPA96 and LPA99 trials, respective-
ly (p=0.73).
Discussion
This study shows a relatively low incidence of CNS
involvement at first relapse in APL patients receiving front-
line therapy with ATRA and anthracycline mono-
chemotherapy without specific CNS prophylaxis. A com-
parison of this incidence in two sequential PETHEMA tri-
als showed that risk-adapted consolidation with ATRA
and reinforced anthracycline for intermediate- and high-
risk patients (LPA99 trial) significantly reduced the inci-
dence of CNS relapse in the latter setting. The relapse-risk
score, which is a composite of WBC and platelet counts,18
and the occurrence of clinical CNS hemorrhage during
induction were the main risk factors for CNS relapse.
Although a sizable proportion of patients experiencing
CNS involvement at first relapse will develop subsequent
bone marrow relapse, some of these patients will still
respond to treatment and may survive over the long term.
Despite the sequential nature of the two trials, there was
an apparent unbiased improvement in the 5-year cumula-
tive incidence of CNS involvement from 3.2% in the
LPA96 trial to 1.2% in the LPA99 trial. The difference was
not significant for this crude comparison, which included
all patients, but became significant when high-risk patients
were analyzed separately. One explanation of the lower
CNS relapse rate in the LPA99 study could be that the
more dose-intensive chemotherapy in this trial reduced
the systemic disease burden, decreasing the risk of seeding
of APL cells in the CNS and, thereby, the incidence of CNS
relapse. Another explanation is that the higher-dose inten-
sity of anthracyclines of the LPA99 trial may offer a more
effective treatment of the CNS sanctuary. Notably, in con-
trast to other anthracyclines, the active metabolite of
idarubicin, idarubicinol, can penetrate the blood–brain bar-
rier.19-21
The variable incidence of CNS involvement at first
relapse observed in different series should be interpreted
with caution. Variables with potential impact on the inci-
dence of this complication may have been unbalanced
and may bias the direct comparison between different
series. Different proportions of patients with leukocytosis
at presentation, a well-recognized risk factor for CNS
relapse,3 is the most obvious potential cause of bias, but
other more subtle factors should also be considered. In
this respect, the sample size and the length of follow-up
are particularly important and usually considered, but
some other factors related to competing events, particu-
larly bone marrow relapse, should also be considered.
Theoretically, a high incidence of bone marrow relapse
can lead to an apparent low incidence of CNS involve-
ment at first relapse. This may explain, at least in part, the
different incidence rates of CNS relapse reported for
series with similar sample size and follow-up.2,3 The
apparently lower incidence of CNS relapse reported by
the European APL Group3 (4 cases among 582 patients)
than in the GIMEMA Group2 (16 cases among 740
patients) was observed in the context of a higher inci-
dence of hematologic relapses in the former (150/582 vs.
131/740). Interestingly, the European APL Group reported
a 2-year cumulative incidence of CNS relapse of 0% in
340 patients treated with ATRA combined with
chemotherapy, including high-dose cytarabine and
intrathecal prophylaxis in patients with WBC counts
Central nervous system relapse in APL
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Figure 1. Cumulative incidence of central nervous system relapse
according to (A) relapse-risk group: intermediate (white blood cell
count ≤10×109/L and a platelet count ≤40×109/L) versus high
(white blood cell count >10×109/L). No relapse occurred among
low-risk patients (WBC count ≤10×109/L and a platelet count
>40×109/L); (B) occurrence of central nervous system hemor-
rhage during induction; and (C) LPA trial and relapse-risk group:
LPA96 versus LPA99.
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greater than 10×109/L.8 However, full evaluation of these
results requires both independent confirmation and a
longer follow-up because a considerable proportion of
CNS relapses may occur more than 2 years after the time
of attainment of the first complete remission (e.g., 5 of 11
cases in our present study).3
As reported previously, our study confirms that APL
patients with high WBC count at diagnosis (>10×109/L)
have an increased risk of CNS relapse.3 However, the
relapse-risk score18 remained as an independent risk factor
in multivariate analysis after removing WBC count from
the regression equation. An additional and novel finding is
the association between the occurrence of clinical CNS
hemorrhage before or during remission induction and sub-
sequent CNS relapse. This has not been reported before
and could have potential therapeutic implications.
Regarding other potential risk factors, some authors have
suggested previously that FLT3-ITD mutations, which
correlate with leukocytosis,22 and an increased expression
of adhesion molecules, such as CD56, can promote
leukemic infiltration in the CNS.23-25 In this study, we were
unable to assess CD56 expression and FLT3-ITD mutation
as predictive factors for CNS relapse in multivariate analy-
sis because of an insufficient number of patients with ade-
quate data. Other factors previously related to
extramedullary relapse, such as age (< 45 years),3 BCR3
isoform,3,4 and development of differentiation syndrome5
were not significant determinants of CNS relapse in our
study.
The low incidence of CNS relapse does not argue in
favor of systematic CNS prophylaxis even in patients with
high-risk APL. The burden for these patients and the poten-
tial risks of additional medical complications (e.g., hemor-
rhage or neurological toxicity)26 following lumbar puncture
would be unlikely to outweigh the possible benefits.
Because there is no clear benefit of systematic CNS pro-
phylaxis, its indication in APL is still a matter of debate.
Based on our results, however, prophylaxis could be con-
sidered for those patients with clinical or radiological signs
of CNS hemorrhage during induction. 
In conclusion, we found a low incidence of CNS involve-
ment at first relapse in newly diagnosed patients with APL
following therapy with ATRA and anthracycline mono-
chemotherapy without specific CNS prophylaxis. CNS
relapse was significantly associated with WBC counts
greater than 10×109/L and CNS hemorrhage during induc-
tion treatment, which emerged as independent prognostic
factors. 
Appendix
The following institutions and clinicians participated in the
study: Argentina (Grupo Argentino de Tratamiento de la
Leucemia Aguda)—Complejo Médico Policia Federal, La Plata;
Fundaleu, Buenos Aires: S. Pavlovsky, G. Milone; Hospital
Clemente Álvarez, Rosario: S. Ciarlo; Hospital de Clínicas,
Buenos Aires; Hospital General San Martín, La Plata: M.
Gelemur; Hospital Rossi, La Plata: S. Saba; Hospital San
Martín de Paraná, Entre Ríos: P. Negri; Instituto Privado de
Hematología, Paraná; Instituto de Trasplante de Médula Ósea,
La Plata: V. Prates; Czech Republic—Faculty Hospital, Brno:
M. Protivankova; Spain (Programa Español de Tratamiento de
las Hemopatías Malignas)—Basurtuko Ospitalea, Bilbao: J. M.
Beltrán de Heredia; Complejo Hospitalario de Segovia: J. M.
Hernández; Complexo Hospitalario Xeral-Calde, Lugo; J. Arias;
Complejo Hospitalario, León: F. Ramos; Fundación Jiménez
Díaz, Madrid: A. Román; Hospital 12 de Octubre, Madrid: J.
de la Serna; Hospital Carlos Haya, Málaga: S. Negri; Hospital
Central de Asturias, Oviedo: C. Rayón; Hospital Clinic,
Barcelona: J. Esteve; Hospital Clínico de Valladolid: F.J.
Fernández-Calvo; Hospital Clínico San Carlos, Madrid: J. Díaz
Mediavilla; Hospital Clínico San Carlos (H. Infantil), Madrid:
C. Gil; Hospital Clínico Universitario, Santiago de Compostela:
M. Pérez; Hospital Clínico Universitario, Valencia: M. Tormo;
Hospital Clínico Universitario Lozano Blesa, Zaragoza: M.
Olave; Hospital de Cruces, Baracaldo: E. Amutio; Hospital del
Mar, Barcelona: C. Pedro; Hospital de Navarra, Pamplona: A.
Gorosquieta; Hospital Dr Negrín, Las Palmas: T. Molero;
Hospital Dr Peset, Valencia: M. J. Sayas; Hospital Dr Trueta,
Girona: R. Guardia; Hospital General de Albacete: J. R. Romero;
Hospital General de Alicante: C. Rivas; Hospital General de
Alicante (Oncología Pediátrica): C. Esquembre; Hospital
General de Castellón: R. García; Hospital General de
Especialidades Ciudad de Jaén: A. Alcalá; Hospital General de
Jerez de la Frontera: A. León; Hospital General de Murcia: M.L.
Amigo; Hospital General de Valencia: M. Linares; Hospital
Germans Trias i Pujol, Badalona: J. M. Ribera; Hospital Insular
de Las Palmas: J. D. González San Miguel; Hospital Juan
Canalejo, A Coruña: G. Debén; Hospital Joan XXIII,
Tarragona: L. Escoda; Hospital La Princesa, Madrid: R. de la
Cámara; Hospital Materno-Infantil de Las Palmas: A. Molines;
Hospital do Meixoeiro, Vigo: C. Loureiro; Hospital Montecelo,
Pontevedra: M. J. Allegue; Hospital Mutua de Terrasa: J. M.
Martí; Hospital Niño Jesús, Madrid: L. Madero; Hospital Ntra.
Sra. de Sonsoles, Ávila: M. Cabezudo; Hospital Ramón y Cajal,
Madrid: J. García-Laraña; Hospital Reina Sofía, Córdoba: R.
Rojas; Hospital Río Carrión, Palencia: F. Ortega; Hospital Río
Hortega, Valladolid: M. J. Peñarrubia; Hospital San Jorge,
Huesca: F. Puente; Hospital San Rafael, Madrid: B. López-Ibor;
Hospital Sant Pau, Barcelona: S. Brunet; Hospital San Pedro de
Alcántara, Cáceres: J. M. Bergua; Hospital Santa María del
Rosell, Cartagena: J. Ibáñez; Hospital Severo Ochoa, Leganés:
P. Sánchez; Hospital Son Dureta, Palma de Mallorca: A. Novo;
Hospital de Tortosa: L. L. Font; Hospital Txagorritxu, Vitoria: J.
M. Guinea; Hospital Universitario del Aire, Madrid: A.
Montero; Hospital Universitario de Salamanca: M. González;
Hospital Universitario La Fe, Valencia: M. A. Sanz, G.
Martín,J. Martínez; Hospital Universitario La Fe (Hospital
Infantil), Valencia: A. Verdeguer; Hospital Universitario La Paz
(Hospital Infantil), Madrid: P. García; Hospital Universitario
Marqués de Valdecilla, Santander: E. Conde García; Hospital
Universitario Príncipe de Asturias, Alcalá de Henares: J. García;
Hospital Universitario Puerta del Mar, Cádiz: F. J. Capote;
Hospital Universitario Puerta de Hierro, Madrid: I. Krsnik;
Hospital Universitario Vall D’Hebron, Barcelona: J. Bueno;
Hospital Universitario Materno-Infantil Vall D’Hebron,
Barcelona: P. Bastida; Hospital Universitario Virgen de la
Arrixaca, Murcia: P. Rosique; Hospital Universitario Virgen de
la Arrixaca (Pediatría), Murcia: J. L. Fuster; Hospital
Universitario Virgen del Rocío, Sevilla: R. Parody; Hospital
Universitario Virgen de la Victoria, Málaga: I. Pérez; Hospital
Virgen del Camino, Pamplona: J. Molina; Hospital Xeral Cíes,
Vigo; C. Poderós; Institut Catala d’Oncologia, Hospitalet de
Llobregat; R. Duarte; The Netherlands (The Dutch–Belgian
Hemato-Oncology Cooperative Group, HOVON)—VU
Medical Center Amsterdam: G. J. Ossenkoppele; Academic
Medical Center, University of Amsterdam: J. van der Lelie;
Erasmus University Medical Center, Rotterdam: B. Lowenberg,
P. Sonneveld, M. Zijlmans; University Medical Center,
Groningen: E. Vellenga; Gasthuisberg Hospital, Leuven: J.
Maertens; OLVG Hospital, Amsterdam: B. de Valk; Den Haag
Hospital, Leyenburg: P.W. Wijermans; Medical Spectrum
Twente Hospital, Enschede: M.R. de Groot; Academic Hospital
Maastricht: H.C. Schouten; St. Antonius Hospital, Nieuwegein:
D.H. Biesma; Sophia Hospital, Zwolle: M. van Marwijk Kooy;
Uruguay, Hospital Maciel, Montevideo: E. de Lisa.
Authorship and Disclosures
PM and MAS, conceived the study, and analyzed and
interpreted the data; PM, BL and MAS wrote the paper;
PM performed the statistical analyses; JD-M, GD, VP,
MT, VR, IP, IF, MV, CRi, JG, JdlS, JE, JMB, CRa, MG, JDG,
SN and SB included data on patients treated in their insti-
tutions, reviewed the manuscript and contributed to the
final draft.
The authors reported no potential conflicts of interest.
Central nervous system relapse in APL
haematologica | 2009; 94(9) | 1249 |
References
1. Evans GD, Grimwade DJ.
Extramedullary disease in acute
promyelocytic leukemia. Leuk
Lymphoma 1997;33:219-29. 
2. Specchia G, Lo Coco F, Vignetti M,
Avvisati G, Fazi P, Albano F, et al.
Extramedullary involvement at
relapse in acute promyelocytic
leukemia patients treated or not with
all-trans retinoic acid: a report by the
Gruppo Italiano Malattie
Ematologiche dell’Adulto. J Clin
Oncol 2001;19:4023-8.
3. de Botton S, Sanz M, Chevret S,
Dombret H, Martin G, Thomas X, et
al. Extramedullary relapse in acute
promyelocytic leukemia treated with
all-trans retinoic acid and chemother-
apy. European APL Group; PETHE-
MA Group. Leukemia 2006;20:35-41. 
4. Liso V, Specchia G, Pogliani EM,
Palumbo G, Mininni D, Rossi V, et al.
Extramedullary involvement in
patients with acute promyelocytic
leukemia: a report of seven cases.
Cancer 1998;83:1522-8.
5. Ko BS, Tang JL, Chen YC, Yao M,
Wang CH, Shen MC, et al.
Extramedullary relapse after all-trans
retinoic acid treatment in acute
promyelocytic leukemia. The occur-
rence of retinoic acid syndrome is a
risk factor. Leukemia 1999;13:1406-8.
6. Breccia M, Carmosino I, Diverio D,
De Santis S, De Propris MS, Romano
A, et al. Early detection of meningeal
localization in acute promyelocytic
leukaemia patients with high present-
ing leucocyte count. Br J Haematol
2003;120:266-70. 
7. Sanz MA, Grimwade D, Tallman MS,
Lowenberg B, Fenaux P, Estey EH, et
al. Guidelines on the management of
acute promyelocytic leukemia: rec-
ommendations from an expert panel
on behalf of the European
LeukemiaNet. Blood 2009; 113:1875-
91. 
8. Adès L, Chevret S, Raffoux E, de
Botton S, Guerci A, Pigneux A, et al. Is
cytarabine useful in the treatment of
acute promyelocytic leukemia?
Results of a randomized trial from the
European Acute Promyelocytic
Leukemia Group. J Clin Oncol 2006;
24:5703-10.
9. Sanz MA, Martín G, González M,
León A, Rayón C, Rivas C, et al. Risk-
adapted treatment of acute promyelo-
cytic leukemia with all-trans retinoic
acid and anthracycline mono-
chemotherapy: a multicenter study
by the PETHEMA Group. Programa
de Estudio y Traitmiento de las
Hemopatías Malignas. Blood 2004;
103:1237-43.
10. Cheson BD, Bennett JM, Kopecky KJ,
Büchner T, Willman CL, Estey EH, et
al. Revised recommendations of the
International Working Group for
Diagnosis, Standardization of
Response Criteria, Treatment
Outcomes, and Reporting Standards
for Therapeutic Trials in Acute
Myeloid Leukemia. J Clin Oncol
2003;21:4642-9.
11. Bolufer P, Barragán E, Sánz MA,
Martín G, Bornstein R, Colomer D, et
al. Preliminary experience in external
quality control of RT-PCR PML-RAR
α detection in promyelocytic
leukemia. Leukemia 1998;12:2024-8. 
12. Frankel SR, Eardley A, Lauwers G,
Weiss M, Warrell RP Jr. The ‘retinoic
acid syndrome’ in acute promyelocyt-
ic leukemia. Ann Intern Med
1992;117:292-6. 
13. Gray RJ. A class of K-sample test for
comparing the cumulative incidence
of a competing risk. Ann Stat 1988;
16:1141-54. 
14. Cox DR. Regression models and life
tables (with discussion). J R Stat Soc B
1972;34:187-220. 
15. Kaplan E, Meier P. Nonparametric esti-
mation from incomplete observation.
J Am Stat Assoc 1958;53:457-81. 
16. Sanz MA, Montesinos P, Vellenga E,
Rayón C, de la Serna J, Parody R, et al.
Risk-adapted treatment of acute
promyelocytic leukemia with all-
trans-retinoic acid and anthracycline
monochemotherapy: long-term out-
come of the LPA 99 multicenter study
by the PETHEMA group. Blood
2008;112:3130-4.
17. de la Serna J, Montesinos P, Vellenga E,
Rayón C, Parody R, León A, et al.
Causes and prognostic factors of
remission induction failure in patients
with acute promyelocytic leukemia
treated with all-trans retinoic acid and
idarubicin. Blood 2008;111:3395-402.
18. Sanz MA, Lo Coco F, Martín G,
Avvisati G, Rayón C, Barbui T, et al.
Definition of relapse risk and role of
nonanthracycline drugs for consoli-
dation in patients with acute
promyelocytic leukemia: a joint
study of the PETHEMA and
GIMEMA cooperative groups. Blood
2000;96:1247-53. 
19. Borchmann P, Hübel K, Schnell R,
Engert A. Idarubicin: a brief overview
on pharmacology and clinical use. Int
J Clin Pharmacol Ther 1997;35:80-3.
20. Dreyer ZE, Kadota RP, Stewart CF,
Friedman HS, Mahoney DH, Kun LE,
M, et al. Phase 2 study of idarubicin in
pediatric brain tumors: Pediatric
Oncology Group study POG 9237.
Neuro Oncol 2003;5:261-7. 
21. Reid JM, Pendergrass TW, Krailo MD,
Hammond GD, Ames MM. Plasma
pharmacokinetics and cerebrospinal
fluid concentrations of idarubicin and
idarubicinol in pediatric leukemia
patients: a Childrens Cancer Study
Group report. Cancer Res 1990;50:
6525-8. 
22. Gale RE, Hills R, Pizzey AR,
Kottaridis PD, Swirsky D, Gilkes AF,
et al. Relationship between FLT3
mutation status, biologic characteris-
tics, and response to targeted therapy
in acute promyelocytic leukemia.
NCRI Adult Leukaemia Working
Party. Blood 2005;106:3768-76. 
23. Marchetti M, Falanga A, Giovanelli S,
Oldani E, Barbui T. All-trans-retinoic
acid increases adhesion to endotheli-
um of the human promyelocytic
leukaemia cell line NB4. Br J
Haematol 1996;93:360-6. 
24. Di Noto R, Lo Pardo C, Schiavone
EM, Ferrara F, Manzo C, Vacca C, et
al. All-trans retinoic acid (ATRA) and
the regulation of adhesion molecules
in acute myeloid leukemia. Leuk
Lymphoma 1996;21:201-9. 
25. Ferrara F, Morabito F, Martino B,
Specchia G, Liso V, Nobile F, et al.
CD56 expression is an indicator of
poor clinical outcome in patients with
acute promyelocytic leukemia treated
with simultaneous all-trans-retinoic
acid and chemotherapy. J Clin Oncol
2000;18:1295-300. 
26. Atra A, Pinkerton CR, Bouffet E,
Norton A, Hobson R, Imeson JD, et
al. Acute neurotoxicity in children
with advanced stage B-non-
Hodgkin’s lymphoma and B-acute
lymphoblastic leukaemia treated
with the United Kingdom Childrens
Cancer Study group 9002/9003 proto-
cols. Eur J Cancer 2004;40:1346-50.
